Abstract
A recent article by Riviere et al. calls for more frequent practical implementation of innovative and efficient approaches in early-phase drug-combination studies. This letter describes our experience in using a novel combination method, one that is overlooked by Riviere et al., in several FDA-approved, ongoing studies at multiple institutions.
Original language | English (US) |
---|---|
Pages (from-to) | 1036-1037 |
Number of pages | 2 |
Journal | Annals of Oncology |
Volume | 26 |
Issue number | 5 |
DOIs | |
State | Published - May 1 2015 |
ASJC Scopus subject areas
- Hematology
- Oncology